A new drug combination shows unexpected synergy against liver fibrosis. A new study reveals that using two drugs together produces a much stronger effect than using either one alone, suggesting a ...
The utilization of biodegradable biomaterials as a therapeutic modality for musculoskeletal tissue regeneration has emerged as a promising avenue for ...
New human clinical trial proves arginine, an amino acid, can modify plaque formation on teeth, thereby protecting ...
The Alpestria-1 study enrolled (in France, USA and Spain) 26 patients with Alport syndrome at high risk of a rapid loss of kidney function despite stable multiple SoC drugs, including ...
FBLG READ THE FULL FBLG RESEARCH REPORT Business Update Approval from HREC for Phase 1/2 Diabetic Foot Ulcer Trial In ...
UK biotech Engitix has raised a $25 million series A extension from existing investor Netherton Investments, investing on behalf of BlueCrest Capital Management co-founder Mike Platt. The funding will ...
Engitix Announces $25 Million Series A Extension Financing by Existing Investor Mike Platt to Advance ECM-Targeted ...
Engitix plans to use the funds for preclinical development across its pipeline in solid tumors and fibrosis, and to expand ...
When a person suffers a stroke, physicians must restore blood flow to the brain as quickly as possible to save their life.
"After a review of BIASURGE®, Vizient’s client-led council agreed this technology offers a unique benefit over other products ...
Injectable filler could help breast cancer patients avoid complex reconstruction procedures, though human trials are still needed.
Aperture Therapeutics, a biotechnology company pioneering next-generation precision medicines for neurodegenerative diseases, today announced the advancement of its matrix metalloproteinase-9 (MMP9) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback